23andMe (ME) Competitors $3.15 -0.28 (-8.16%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ME vs. EMBK, VLTA, SKIN, HLLY, TKNO, BTMD, ACRS, CMPS, ACIU, and JSPRShould you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Embark Technology (EMBK), Volta (VLTA), Beauty Health (SKIN), Holley (HLLY), Alpha Teknova (TKNO), biote (BTMD), Aclaris Therapeutics (ACRS), COMPASS Pathways (CMPS), AC Immune (ACIU), and Jasper Therapeutics (JSPR). 23andMe vs. Embark Technology Volta Beauty Health Holley Alpha Teknova biote Aclaris Therapeutics COMPASS Pathways AC Immune Jasper Therapeutics 23andMe (NASDAQ:ME) and Embark Technology (NASDAQ:EMBK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation. Is ME or EMBK more profitable? Embark Technology has a net margin of 0.00% compared to 23andMe's net margin of -318.39%. Embark Technology's return on equity of -91.32% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets 23andMe-318.39% -129.98% -62.37% Embark Technology N/A -91.32%-78.87% Does the MarketBeat Community believe in ME or EMBK? 23andMe received 9 more outperform votes than Embark Technology when rated by MarketBeat users. Likewise, 60.00% of users gave 23andMe an outperform vote while only 37.50% of users gave Embark Technology an outperform vote. CompanyUnderperformOutperform23andMeOutperform Votes1260.00% Underperform Votes840.00% Embark TechnologyOutperform Votes337.50% Underperform Votes562.50% Do insiders and institutionals hold more shares of ME or EMBK? 36.1% of 23andMe shares are owned by institutional investors. Comparatively, 78.0% of Embark Technology shares are owned by institutional investors. 26.3% of 23andMe shares are owned by insiders. Comparatively, 31.6% of Embark Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, ME or EMBK? 23andMe has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Embark Technology has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Do analysts recommend ME or EMBK? 23andMe currently has a consensus price target of $9.40, indicating a potential upside of 198.41%. Given 23andMe's stronger consensus rating and higher possible upside, research analysts plainly believe 23andMe is more favorable than Embark Technology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 23andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Embark Technology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, ME or EMBK? Embark Technology has lower revenue, but higher earnings than 23andMe. Embark Technology is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio23andMe$219.64M0.35-$666.70M-$25.32-0.12Embark TechnologyN/AN/A-$103.16M-$7.73-0.37 Does the media refer more to ME or EMBK? In the previous week, 23andMe had 12 more articles in the media than Embark Technology. MarketBeat recorded 12 mentions for 23andMe and 0 mentions for Embark Technology. Embark Technology's average media sentiment score of 0.00 beat 23andMe's score of -0.54 indicating that Embark Technology is being referred to more favorably in the news media. Company Overall Sentiment 23andMe Negative Embark Technology Neutral Summary23andMe and Embark Technology tied by winning 8 of the 16 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get 23andMe News Delivered to You Automatically Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ME vs. The Competition Export to ExcelMetric23andMePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.08M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.124.8587.8613.46Price / Sales0.35374.821,228.8287.66Price / Cash1.1652.5939.5136.27Price / Book0.7610.216.946.30Net Income-$666.70M$153.61M$119.12M$225.93M7 Day Performance-17.54%-2.00%-1.84%-1.32%1 Month Performance-35.58%-7.47%-3.65%0.60%1 Year Performance-81.76%31.80%31.64%26.23% 23andMe Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ME23andMe1.2334 of 5 stars$3.15-8.2%$9.40+198.4%-82.6%$84.08M$219.64M-0.12770EMBKEmbark TechnologyN/A$2.88flatN/AN/A$69.26MN/A-0.37329VLTAVoltaN/A$0.86flatN/AN/A$145.10M$50.23M-0.57253SKINBeauty Health2.6897 of 5 stars$1.49-7.5%$2.55+71.1%-36.3%$200.29M$398M0.001,030Analyst RevisionPositive NewsHLLYHolley3.624 of 5 stars$2.65+1.1%$6.63+150.0%-35.0%$313.87M$659.70M20.381,633Short Interest ↓TKNOAlpha Teknova0.7174 of 5 stars$7.74+24.6%$5.00-35.4%+279.4%$331.04M$36.68M0.00240Gap UpHigh Trading VolumeBTMDbiote3.1975 of 5 stars$6.06-0.5%$8.39+38.4%+19.8%$330.19M$185.36M23.31194ACRSAclaris Therapeutics3.948 of 5 stars$3.96-13.7%$8.80+122.2%+321.2%$327.87M$31.25M0.0086Analyst UpgradeInsider TradeAnalyst RevisionNews CoverageGap DownCMPSCOMPASS Pathways2.8558 of 5 stars$4.66-2.1%$30.67+558.1%-23.0%$325.68MN/A0.00120Short Interest ↓ACIUAC Immune2.2991 of 5 stars$3.24-0.9%$12.00+270.4%+0.0%$323.54M$16.48M0.00140Positive NewsJSPRJasper Therapeutics2.6633 of 5 stars$20.98+1.4%$74.86+256.8%+227.3%$310.38MN/A0.0020 Related Companies and Tools Related Companies EMBK Competitors VLTA Competitors SKIN Competitors HLLY Competitors TKNO Competitors BTMD Competitors ACRS Competitors CMPS Competitors ACIU Competitors JSPR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ME) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ME Stock Alerts